Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -77.12% | 75.27% | 58.36% | 55.68% | 63.75% |
| Total Depreciation and Amortization | 7.23% | -61.59% | -83.20% | -87.23% | -80.61% |
| Total Amortization of Deferred Charges | 2.50% | -11.73% | 4.58% | 4.64% | 4.70% |
| Total Other Non-Cash Items | 33.24% | 49.52% | 62.76% | 78.11% | 0.29% |
| Change in Net Operating Assets | -2,307.48% | -542.63% | -569.79% | -675.04% | 90.73% |
| Cash from Operations | -266.66% | 82.54% | 81.72% | 94.06% | 85.64% |
| Capital Expenditure | -234.25% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -100.00% | -65.82% |
| Cash from Investing | -101.40% | -100.75% | -101.03% | -100.24% | -65.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.26% | 60.75% | 45.86% | -10.19% | -23.45% |
| Repurchase of Common Stock | -1,718,885.00% | -1,718,885.00% | -1,718,650.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,477.33% | 2,906.61% | 2,247.43% | 2,660.99% | -83.71% |
| Cash from Financing | -112.69% | 71.39% | 258.00% | -8.29% | 9.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -237.06% | 247.00% | 131.60% | 247.47% | 247.33% |